Results from the completed QuANTUM-R phase 3 study in patients with relapsed/refractory FLT3–ITD-mutated AML, quizartinib (30-mg starting dose with escalation to 60 mg once daily; n = 245) showed prolonged overall survival versus standard chemotherapy (n = 122; median 6.2 months vs. 4.7 months, respectively; hazard ratio: 0.76; P = 0.02), with a greater proportion of patients undergoing hematopoietic stem cell transplantation (32% vs. 11%, respectively) [9]. This evidence concerns the gene FLT3 and acute myeloid leukemia.